The report suggests with moderate certainty that all 3 therapies offer a small or substantial net health benefit and with a high certainty of at least a small net health benefit.
Data from the phase 3b FOCUS trial demonstrates fremanezumab’s superior efficacy and tolerability in the prevention of migraine.
At the recent American Headache Society meeting, researchers detailed the manifold risks of opioid use in patients with migraine.
Emgality (galcanezumab-gnlm) is the first FDA-approved drug that reduces the frequency of headache attacks.
Take this brief quiz to test your knowledge of recent recommendations from the American Headache Society for the prevention and acute management of migraine.
Is there a connection between this patient’s ocular symptoms and migraines?
The patient has a history of migraine. Is this another attack—or is something else going on?
A review of systemic medications for dermatologic diseases describes a wide range of adverse events, which range from mild and reversible to permanent and potentially fatal.
With a plethora of issues currently being debated in the field of sports neurology, Dr Seifert explores the top 5.
Can treatment of subclinical hypothyroidism help diminish frequency and severity of migraines? This study suggests that levothyroxine can do both.